Navigation Links
Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
Date:7/29/2011

to $200 million.

With respect to other guidance, Amgen continues to expect the adjusted tax rate for 2011 to be in the range of 15 percent to 16 percent.  This reflects the impact of the foreign tax credit associated with the Puerto Rico excise tax.  

The Company still expects 2011 capital expenditures to be approximately $600 million.

Second Quarter Product and Pipeline UpdateThe Company provided the following information on selected products and clinical programs:

EPOGEN/Aranesp: The Company discussed modifications to U.S. Prescribing Information for use of erythropoiesis-stimulating agents in chronic kidney disease that were finalized on June 24th.

Prolia:  The Company announced that a small Phase 3 Bone Mineral Density study in men with osteoporosis met all endpoints and the safety data were consistent with what has been previously reported in other populations.

XGEVA:  The Company discussed the European Medicines Agency marketing authorization it received on July 15th for the prevention of skeletal-related events in adults with bone metastases from solid tumors.

The Company also discussed that it submitted a supplemental Biologics License Application on June 27th to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

Vectibix:  The Company discussed the Committee for Medicinal Products for Human Use (CHMP) positive opinion it received in the European Union for use in combination with chemotherapy in first- and second-line metastatic colorectal cancer patients with wild-type KRAS.

The Company announced that it received Complete Response Letters from the FDA on the first- and second-line metastatic colorectal cancer supplemental Biologics License Applications.  The FDA has requested additional information from the ‘181 and &
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
3. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Genesis Biopharma, Inc. (OTC Bulletin Board: ... therapies, announces that CEO Robert Brooke will present a company ... 12, 2011, at 9:45 a.m. Pacific time.  The conference is ... Union Square. "We look forward to discussing our ...
... The pharmaceutical industry,s steep patent cliff and ... executives to uncover opportunities for sustainable growth in ... branded products to extend patent life. For pharma ... a therapeutic advantage and become part of lifecycle ...
Cached Medicine Technology:Genesis Biopharma to Present at 2011 Biotech Showcase Conference 2Report Highlights Successful Strategies for Bringing FDC Products to Market 2
(Date:7/12/2014)... 12, 2014 The rise in the ... for new advanced network architectures to suit the upsurge. ... industry with increasing cloud storage technologies. The data traffic ... more mobility devices. This has resulted in larger and ... driving forces for the SDN market. , The North ...
(Date:7/12/2014)... 2014 Demand Response Management Systems is ... in reducing the imbalance between energy supply and demand. ... been rolled out (due to increasing pressure on the ... helps in controlling residential appliances and thermostats for load ... North American region, and with government mandates and benefits ...
(Date:7/12/2014)... (HealthDay News) -- If you make exercise fun, you,ll eat ... experiment, 56 adults were led on a 1.4-mile walk and ... a scenic walk. The participants were given lunch after the ... outing ate 35 percent more chocolate pudding for dessert than ... In another experiment, 46 adults were given mid-afternoon snacks after ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Using ... so one of two inventors from Ashland, Va., decided ... do this. "This inspired us to conceive of our ... of the patent-pending KIDNEY KOVER, which provides an inconspicuous ... It avoids embarrassment, as well as promotes comfort and ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... ban production of low-grade plastic from Wednesday, Chief Minister ... the World Environment Day. ,Bhattacharya urged the ... their assistance in formulating an environment-friendly policy. ... plastic production (below 40 micron) in West Bengal. Earlier ...
... have slightly higher survival rates when treated with the ... according to a study in the June 6 Journal ... cisplatin chemotherapy should remain the standard of care for ... prefer carboplatin to cisplatin because it has fewer side ...
... fifteen months after the 9/11 terrorist attacks, President George W. ... Executive Office Building next door to the White House ... laboratories, and we believe that regimes hostile to the United ... that a smallpox attack is imminent. Yet it is prudent ...
... They live longer than almost anyone in the region. Far ... scourges of the poor as parasites, TB, malaria, even ... at low cost, right in the neighborhood. ,The success ... recent Michael Moore documentary pouring scorn on healthcare in US ...
... disorder (BPD) can be reduced by an intensive ... (TFP) thereby reducing the symptoms and improving their social ... of the American Journal of Psychiatry, a premier psychiatry ... affecting about 1% of the United States population, has ...
... by bird flu, have found preliminary evidence which suggests ... warned Wednesday . ,The head of Indonesia's ... told reporters the human fatality rate had increased in ... with 74.5 percent the previous year. ,Krisnamurthi ...
Cached Medicine News:Health News:New Smallpox Vaccine Contract: Five Years in the Making 2Health News:Cuba is Exporting Healthcare Now 2Health News:Cuba is Exporting Healthcare Now 3Health News:Cuba is Exporting Healthcare Now 4Health News:Cuba is Exporting Healthcare Now 5Health News:Intensive Psychotherapy Provides Helping Hand in Borderline Personality Disorder. 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: